-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewNet Present Value Model: 89bio Inc’s Pegozafermin
Empower your strategies with our Net Present Value Model: 89bio Inc's Pegozafermin report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Tipiracil Hydrochloride + Trifluridine) in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Tipiracil Hydrochloride + Trifluridine) in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Tipiracil Hydrochloride + Trifluridine) in Rectal Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Follicular Lymphoma Drug Details: AT-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Metastatic Pancreatic Cancer Drug Details: LNS-8801 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vas-01 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vas-01 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vas-01 in Solid Tumor Drug Details: Vas-01 (Recombinant fusion protein) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Metastatic Biliary Tract Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Colorectal Cancer Drug Details: Lenvatinib mesylate (Lenvima...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Metastatic Melanoma Drug Details: Lenvatinib mesylate (Lenvima...